(NasdaqGM:VERA), BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of […]
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer GlobeNewswire August 08, 2025 – Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TArgeting
Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025 Company to host an investor conference call and webcast at 4:30 pm ET GlobeNewswire August 08, 2025 NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) — Hyperion Defi, Inc. (NASDAQ: HYPD), the first U.S. public company to build a strategic treasury around the
Capital Clean Energy Carriers Corp. Announces Annual Meeting of Shareholders GlobeNewswire August 08, 2025 ATHENS, Greece, Aug. 08, 2025 (GLOBE NEWSWIRE) — The Board of Directors of Capital Clean Energy Carriers Corp. (NASDAQ: CCEC) (the “Corporation” or “CCEC”) has called an annual meeting of shareholders to be held at the Corporation's headquarters in Greece on
Commerce to Present at Upcoming Investor Conference GlobeNewswire August 08, 2025 AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) — Commerce.com, Inc. (Nasdaq: CMRC) (formerly BigCommerce Holdings, Inc.), a provider of an open, intelligent ecosystem of technology solutions that empower businesses to unlock data potential and deliver seamless, personalized experiences at scale, today announced the following
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates GlobeNewswire August 08, 2025 FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment Significant regulatory and pipeline advancements achieved including FDA waiver of additional safety studies
Femasys Announces Second Quarter Financial Results for 2025 GlobeNewswire August 08, 2025 — Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio — ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced
Phunware Reports Second Quarter 2025 Financial Results GlobeNewswire August 08, 2025 Delivers Strong First Half with Key Product Milestones and Customer Momentum Strong Liquidity Powering New Technology Improvements, AI Integration and Corporate Initiatives AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) — Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), a leader in enterprise cloud solutions
Amwell makes grant to new employees under inducement plan GlobeNewswire August 08, 2025 BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) — Amwell(R) (NYSE: AMWL), a leading technology-enabled care platform provider, announces that on August 8, Amwell made grants of RSUs covering an aggregate of 76,198 shares of its Class A common stock to two new employees.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire August 08, 2025 BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of